Simoa Custom Immunoassay Development Platform: Up to 1000-Fold Sensitivity Conversion over ELISA

In drug discovery and translational biomarker research, proprietary drug targets, post-translationally modified proteoforms, neoantigens, and rare disease biomarkers frequently lack commercially available high-sensitivity assay kits. While conventional plate ELISAs provide basic proof-of-concept, their nanogram-to-picogram sensitivity limits (LLOQs ~10 to 50 pg/mL) frequently fail to quantify low-abundance circulating analytes in basal blood or serial micro-samples.

Quanterix Simoa Homebrew Custom Assay Development bridges this gap. By conjugating high-affinity monoclonal or polyclonal capture antibodies onto paramagnetic carboxylated beads (via carbodiimide EDC/NHS crosslinking) and optimizing biotinylated detector antibody chemistry, Creative Proteomics converts standard ligand-binding assays into ultra-sensitive digital single-molecule assays. When beads are partitioned into 216,000 femtoliter microwells, digital Poisson counting delivers up to a 1,000-fold increase in analytical sensitivity, pushing LLOQs down into the femtogram/mL and sub-pg/mL regime.

Key Advantages of Custom Simoa Development with Creative Proteomics

  • 1,000-Fold Sensitivity Leap: Transforms undetectable or borderline ELISA targets into robustly quantifiable digital readouts with 100% basal detection rates.
  • Proprietary Target Independence: Fully compatible with client-supplied proprietary antibodies, recombinant proteins, peptides, and antisense oligonucleotides.
  • Micro-Volume Efficiency: Reduces sample volume requirements from 100–200 μL (conventional ELISA) down to 15 μL net volume, preserving small-animal cohorts.
  • Multiplex Capability: Ability to engineer custom 2-plex, 3-plex, or 4-plex panels using fluorescently dye-encoded bead populations.